contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


toleranzia-ab-conducts-successful-safety-study-of-tol2-in-blood-samples-from-patients-with-myasthenia-gravis

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Toleranzia is a research company focused on the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology focused on the muscular disease myasthenia gravis. In addition, the technology has been used in other areas such as diabetes and multiple sclerosis. Research collaboration is done together with external partners within the field. The head office is based in Gothenburg.

Toleranzia

Toleranzia previously reported the successful completion of a GLP-toxicology study of TOL2, a regulatory milestone for approval of an investigational new drug for first in human testing. To ...

<div class="mfn-preamble">Toleranzia previously reported the successful completion of a GLP-toxicology study of TOL2, a regulatory milestone for approval of an investigational new drug for first in human testing. To further establish the safety of TOL2, the company recently performed an additional and unique safety study in human tissue.</div><div class="mfn-body">In this study, blood samples from six MG patients were individually exposed to different concentrations of TOL2 in a system at 37°C mimicking the normal human blood circulation. This safety study is aimed to assess unwanted immune system activation and effects on blood cells. &nbsp; The results from this patient-based test system identified no signals of inflammatory immune activation or negative effects on blood cell counts attributable to TOL2 at the doses tested. &nbsp; "We are very excited about the positive results from this study in which we had an exceptional opportunity to test TOL2 directly in samples from our target patient population. This adds highly valuable and relevant information on the safety profile of TOL2 in preparation for the upcoming clinical study in MG patients", comments Charlotte Fribert, CEO of Toleranzia. &nbsp; &nbsp; For further information, please contact Charlotte Fribert - CEO, Toleranzia AB Tel: +46 763 19 98 98 Email: <a rel="noopener" href="mailto:charlotte.fribert@toleranzia.com">charlotte.fribert@toleranzia.com</a> &nbsp; About Toleranzia AB (publ) Toleranzia AB (publ) develops drugs that utilize the immune system's own power to treat autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, only reduce the symptoms. They have the potential to be the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, <a rel="noopener" href="mailto:CA@mangold.se">CA@mangold.se</a>, is the company's Certified Adviser.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/ab86771d-832c-4a52-921e-e6716aabc8a8/toleranzia-ab-conducts-successful-safety-study-of-tol2-in-blood-samples-from-patients-with-myasthenia-gravis.pdf" class="mfn-generated mfn-primary">Toleranzia AB conducts successful safety study of TOL2 in blood samples from patients with myasthenia gravis</a></div>

Toleranzia AB conducts successful safety study of TOL2 in blood samples from patients with myasthenia gravis

Federal Reserven korkopäätös: Kiire loppui tähän

Drug development investment: Value creation through M&As and licensing agreements

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Laskuviikko takana Euroopassa, EKP:n viesti sai lopulta velkakirjakorot nousuun

Stay up to date with our newsletter